Chemical engineering seemed like a sensible choice for Shon who is coming from a family of engineers. At the age of 18 the trajectory of his path took a turn when he blindly sent out 30 resumes and received one offer from a cardiologist to work in his lab. Looking back, he realizes that this was the first time “who” luck shaped his career in medicine.
This week’s guest on Parallax is Dr Shon Chakrabarti, Vice President Medical Affairs at Inari Medical.
In this rich and candid episode, Dr Chakrabarti recalls the early stages of his career and the non-linear route that led to his transition from an interventional cardiologist to working on devices that focus on improving the treatment of deep vein thrombosis (DVT). This journey was paved by self-reflection, hunger for tangible results, and connections with mentors who dared to dream big and wished the same for their mentees.
How did the transition from bedside medicine to industry shape the identity of Dr Chakrabarti? What are the highlights of his job as the Vice President Medical Affairs? What is his advice for early career cardiologists?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest, @shonmd hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Dr Ankur Kalra’s guests this week are Dr Martha Gulati, internationally recognized cardiologist specializing in Women and Heart Disease, Heart Disease Prevention and Dr Devesh Rai, first year cardiology fellow at Rochester General Hospital.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.